对于年龄为75-80岁之间的患者应采用每日300mg的剂量,即每次一粒150mg的胶囊,每日两次。当血栓栓塞风险较低而出血风险较高时,可考虑每日220mg的剂量,即每次一粒110mg的胶囊,每日两次,由医生酌情自行决定。 对于年龄为80岁及以上的患者,由于其出血风险增加,因此应采用每日220mg的剂量,即每次一粒110mg的胶囊,每日两次。
PRADAXA Capsules can be used in pediatric patients aged 8 to less than 18 years of age who are able to swallow the capsules whole. Other age-appropriate pediatric dosage forms of dabigatran etexilate are available for pediatric patients less than 8 years of age. For the treatment of VTE in ...
Avoid antacids within 24 hours after surgery, or dabigatran may not work as well. If you have stomach upset while taking this medication, take it with food.Swallow the capsules whole with a full glass of water (8 ounces/240 milliliters). Do not crush, chew, or break open the capsules...
Pradaxa capsules are supplied in 75 mg, 110 mg, and 150 mg strengths for oral administration. Each capsule contains dabigatran etexilate mesylate as the active ingredient: 150 mg dabigatran etexilate (equivalent to 172.95 mg dabigatran etexilate mesylate), 110 mg dabigatran etexilate (equivalent to ...
The article offers information on thrombin inhibitor Dabigatran Etexilate mesylate including its dosage, indications, and clinical implications.Elliott, William T.Internal Medicine AlertU.S. Food and Drug ...
Learn how Pradaxa® (dabigatran etexilate capsules) can help lower your risk of stroke due to AFib not caused by a heart valve problem. Read for ISI, Med Guide and PI.
Learn how Pradaxa® (dabigatran etexilate capsules) can help lower your risk of stroke due to AFib not caused by a heart valve problem. Read for ISI, Med Guide and PI.
Pradaxa® (dabigatran etexilate mesylate) capsules is indicated: to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation; for the treatment of deep venous thrombosis and pulmonary embolism in patients who have been treated with a parenteral anticoagulant fo...
Indications and UsagePradaxa® (dabigatran etexilate mesylate) capsules is indicated: to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation IMPORTANT SAFETY INFORMATION ABOUT PRADAXA WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA ...